cbl0137
Small moleculeexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01905228)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DNABINDING AGENT
DNA binding agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cbl0137
- cbl0137
- cbl0137
- cblc137
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05498792 | Early Phase 1 (Phase 1) | Nov 30, 2022 | Incuron, Temple University |
| NCT04870944 | Phase 1/Phase 2 (Phase 2) | Dec 10, 2021 | Incuron, National Cancer Institute (NCI) |
| NCT03727789 | Phase 1 | Jul 28, 2019 | Incuron, State University of New York, Buffalo |
| NCT02931110 | Phase 1 | Jan 1, 2017 | Augusta University, Incuron |
| NCT01905228 | Phase 1 | Jul 1, 2013 | Case Western Reserve University, Incuron, State University of New York, Buffalo, University of Texas, San Antonio |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incuron | For profit | 5 | 2 | 2 | 2013 |
| State University of New York, Buffalo | Academic/Hospital | 2 | 1 | 1 | 2013 |
| Augusta University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2021 |
| Temple University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 0 | 1 | 2013 |
7 organizations
Page 1 / 1